Key result
Hemodynamic pathways and novel biomarkers offer key diagnostic and therapeutic targets in cardiorenal syndrome.
Why the study?
Elucidating hemodynamic and non-hemodynamic pathways and biomarkers in cardiorenal syndrome is needed to provide diagnostic and treatment tools.
Understanding the hemodynamic and non-hemodynamic pathways in cardiorenal syndrome is crucial for developing new diagnostic, prognostic, and therapeutic tools.
Answers are grounded in this paper and cite their sources.
Requires prospective validation before clinical use in cardiorenal syndrome; leaves open targeted therapies based on these pathways.
Cardiorenal syndrome encompasses complex multifactorial facets and carries significant morbidity and mortality worldwide. The bi-directional relationship between the heart and kidneys, where dysfunction in one organ worsens the function of the other, has been the leading motor for research in the last few years. In the pathophysiological process, small noncoding RNAs, epigenetics, vascular growth factors, oxidative stress, hemodynamic factors, and biomarkers play a pivotal role in the development of cardiorenal syndrome. It is therefore important to elucidate all the mechanisms in order to provide diagnostic and treatments tools. This review summarizes the hemodynamic and non-hemodynamic pathways along with biomarkers that could be the next target for diagnosis, treatment, and prognosis in cardiorenal syndrome.
No takes yet. Share an insight, caveat, or question.
Buliga-Finiș et al. (2022) conducted a review in Cardiorenal syndrome. Hemodynamic and non-hemodynamic pathways, along with novel biomarkers, play a pivotal role in cardiorenal syndrome and represent potential targets for diagnosis, treatment, and prognosis.
Synapse has enriched 10 related papers. Consider them for comparative context: